JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non–small Cell Lung CancersSean P. Pitroda, Nikolai N. Khodarev|Molecular Cancer Therapeutics|2018Cited by 23
Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial.Minas P. Economides, Scot A. Niglio, Peter H. O’Donnell et al.|Journal of Clinical Oncology|2023Cited by 8